Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib versus placebo maintenance after first-line chemotherapy plus bevacizumab in advanced ovarian cancer
2014-004027-52Phase 3Active
- Sponsor
- ARCAGY
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Olaparib maintenance plus bevacizumab with Placebo maintenance plus bevacizumab (2 arms). Primary endpoint: Progression-free survival 1. Started May 2015; status: active.
02
Drugs
olaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2014-004027-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004027-52.